Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists
- 1 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 40 (7), 2865-2871
- https://doi.org/10.1007/s10067-021-05617-7
Abstract
Familial Mediterranean fever (FMF) is characterized by recurrent attacks of fever, serositis, and arthritis. Some patients suffer from associated inflammatory conditions and damage related to FMF that may potentially impair work productivity which have not been studied to date. Consecutive FMF patients who were attending a tertiary referral center and age-and sex-matched healthy subjects enrolled into the study. Disease activity was assessed with autoinflammatory disease activity index (AIDAI) and patient global assessment. Damage was evaluated using Autoinflammatory Disease Damage Index (ADDI). Quality of life (QoL) and work productivity were determined with 36-Item Short Form Health Survey (SF-36) and Work Productivity and Activity Impairment Specific Health Problem v2.0 (WPAI:SHP), respectively. There were 111 FMF patients, 60 female (54%), mean age 32.7±8.7 years. There were significant impairments in all domains of the SF-36 QoL in FMF patients. Of the 111 patients enrolled, 65 (58.6%) were employed in a paid work. Mean% ±SD impairment in work productivity both assessed as absenteeism (9.3±23.2% vs. 0.7±2.6, p=0.013) and presenteeism (35.2±32.6% vs. 9.6±14.7, p<0.001) were significantly higher in FMF patients compared to healthy subjects. Impairment in work productivity was correlated with the number of attacks, disease activity, colchicine resistance, and disease-associated damage. Impairment was most significant in colchicine-resistant FMF patients but lower in those on interleukin (IL)-1 antagonist treatments. FMF causes significant work impairment and reduced QoL which is associated with disease activity and damage. The use of IL-1 antagonists may help to improve work productivity and QoL in FMF patients with frequent attacks.This publication has 26 references indexed in Scilit:
- Familial Mediterranean fever, from pathogenesis to treatment: a contemporary reviewTURKISH JOURNAL OF MEDICAL SCIENCES, 2020
- Predictors of persistent inflammation in familial Mediterranean fever and association with damageRheumatology, 2020
- The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative ReviewFrontiers in Immunology, 2020
- Colchicine intolerance in FMF patients and primary obstacles for optimal dosingTURKISH JOURNAL OF MEDICAL SCIENCES, 2020
- Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort studyRheumatology International, 2019
- Detection of Familial Mediterranean Fever attacks by using a connected activity tracker and assessment of impact of attacks to daily physical activities: a pilot studyClinical Rheumatology, 2019
- Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patientsClinical Rheumatology, 2018
- EULAR recommendations for the management of familial Mediterranean feverAnnals Of The Rheumatic Diseases, 2016
- The factors considered as trigger for the attacks in patients with familial Mediterranean feverRheumatology International, 2012
- Managing arthritis and employment: Making arthritis‐related work changes as a means of adaptationArthritis Care & Research, 2004